5 hasil untuk "Kapiris, Matthaios"
Menampilkan 1–5 · 0,28 detik · RSS
-
Artikel Jurnal Teks lengkap
Clinical and experimental treatment of advanced melanoma with a focus on immunotherapy
Melanoma is currently the fifth most common cancer in the UK, and its incidence is rising. Although surgery is curative for many early-stage tumours, advanced disease which is inoperable has historically also been considered incurable. Recent and rapid advances in cancer immunotherapy, particularly…
-
Artikel Jurnal Teks lengkap
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
PURPOSE: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities. However, prospective DPYD genotyping has not yet been implemented in routine clinical practice…
-
Artikel Jurnal Teks lengkap
Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
Background/Aim: During recent years, a survival advantage was reported for first-line treatment of advanced pancreatic cancer with two new regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, over gemcitabine monotherapy. Gemcitabine/nab-paclitaxel administration on days 1, 8 and 15 of a 4-week…
-
Artikel Jurnal Teks lengkap
Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study
SIMPLE SUMMARY: Non-small cell lung cancer in young adults spans all ethnic backgrounds and is associated with advanced disease and poor outcomes. Identification of genetic changes that are associated with disease and can subsequently be targeted with specific therapies is associated with improved…
-
Artikel Jurnal Teks lengkap
Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma
BACKGROUND: The majority of patients with melanoma develop immune-related adverse events (irAEs), and over half do not respond to anti-PD-1 (Programmed cell death protein 1) checkpoint inhibitor (CPI) immunotherapy. Accurate predictive biomarkers for both response to therapy and development of…